Leiden researchers, led by Sebastian Pomplun developed a new method to screen hundreds of thousands of molecules for drug discovery, using mass spectrometry instead of DNA tags. ‘We wanted to make drug discovery faster and more accessible.’

How do you know if a drug will actually work? The Leiden-based spin-off Omivera is developing a new technology that could provide clearer answers. The young company received a seed investment from the investment fund UNIIQ to support its development.

Chronic pain, nausea or vomiting due to chemotherapy. If you suffer from such ailments, medicinal cannabis can be a godsend. Though a downside is that it can make patients high. Therefore, Leiden researchers from the Oncode Institute are investigating alternatives that do not make you high. In Nature…

One in two people will be diagnosed with cancer. World Cancer Day on 4 February raises awareness of the impact of this devastating disease. Leiden University is conducting various studies aimed at preventing and controlling cancer. Below are just a few examples.

The AtheroNeth consortium received €6 million from the Dutch Heart Foundation to gain a better understanding of the differences in disease progression among patients with atherosclerosis. The ultimate goal is to enable personalised treatment.

How can you ensure that more experimental drugs reach the finish line? At the moment, only one in twenty cancer drugs that are tested on humans makes it to the market. This is an enormous loss for patients and society. With a grant from the National Growth Fund, Oncode-PACT aims to efficiently select…

Two Leiden researchers have been awarded ERC Proof of Concept grants. These grants, each worth EUR 150,000, will help the grantees in their efforts to bridge the gap from basic science to real-life applications

For her bachelor’s thesis, Molecular Science and Technology student Madouc Bergers synthesized her own molecule that can inhibit the breakdown of sugars. Although most students do not even manage to make one building block, Madouc made three. Partly because of this, she has been nominated for the Science…

A new class of polymers has been used in patients for the first time. The compound is the first new drug solubilising agent in decades. Introduced in 2014 by chemist Matthias Barz from Leiden University, it offers a unique alternative to current options.

When a bacterium becomes resistant to one antibiotic, it may sometimes become more sensitive to another. This biological side-effect offers an unexpected opportunity in the fight against antibiotic resistance.